Univercells is a company offering bio manufacturing solutions in Belgium. The company develops automated cell culture and virus production bioreactors for biotechnology and healthcare sectors. Founded 2013 in Gosselies, Hainaut, Belgium by Hugues Bultot, Univercells has raised a total of $94.5M in funding over six rounds. Their latest funding was raised on February 18, 2020 from a venture round. The company is funded by 10 investors, with Kohlberg Kravis Roberts and ClubDeal as its most recent investors. It delivers novel bio-manufacturing platforms and solutions aimed at making biologics available and affordable by relying on proprietary core technologies and a continuous process intensification approach.
Univercells launched Exothera, a contract development and manufacturing organization (CDMO), in March, 2020 that will focus on viral vectors targeting cell and gene therapy and vaccine development. Exothera will run in Jumet Belgium. Exothera services will include helping companies streamline development and production of viral vectors and building custom commercial facilities on site. Exothera plans to work on vaccines for COVID-19 through supporting vaccine innovators and providing manufacturing services.
Univercells raises a $18,800,000 series B round from Global Health Investment Fund.
Univercells raises a $3,560,000 series A round from Takeda Ventures.
Founder & CEO
Rodolphe de Spoelberch
Documentaries, videos and podcasts
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.